Abbott has launched its new vascular imaging platform powered by Ultreon 1.0 Software in India. This first-of-its-kind intra-vascular imaging software combines optical coherence tomography (OCT) with the power of artificial intelligence (AI) providing physicians a comprehensive view of blood flow and blockages within coronary arteries.
The innovative imaging software can automatically differentiate between a calcified and non-calcified blockage, detect the severity of calcium-based blockages and measure vessel diameter. In addition, it helps physicians guide precise stent deployment, ensure optimal stent expansion and apposition with instantaneous display of results to enhance precision during coronary stenting procedures.
Unlike traditional imaging methods such as conventional angiography, Abbott’s OCT technology uses near-infrared light to provide high-definition, precise imaging from within a blood vessel, allowing physicians to capture information from even the most complex patient anatomy. The software enables a streamlined workflow that facilitates accurate and faster decision-making, reduces ambiguities to focus on what's most important: caring for the patient and improving their quality of life.
With the launch of Ultreon 1.0 Software, Abbott is further leveraging OCT technology to help physicians make better treatment decisions for their patients. Recent data show that physicians altered their treatment strategy in 88% of coronary artery blockages based on new information provided by OCT when used with MLD MAX, a new workflow that helps guide stenting decisions and provide physicians with treatment strategies to optimize stent placement.
“This new software for OCT provides us with an automated and comprehensive view of the coronary arteries. This certainly facilitates better decision-making while guiding precision stent placement,” said Dr. Ankur Phatarpekar from Symbiosis Speciality Hospital, Mumbai. “These types of technologies are instrumental in providing the best care for our patients.”
In market research commissioned by Abbott titled Beyond Intervention in August 2020, physicians and administrators identified technology as a critical component to improving patient outcomes across the healthcare continuum. According to the research, 83.2% of physicians agreed that advances in diagnostic and treatment technologies, such as OCT, have translated to tangible improvements in patient care.
Ultreon Software is an example of technology designed to augment physician decision-making, particularly when combined with established tools providing comprehensive physiological assessment of coronary blood flow and severity of blockages. With the rising burden of cardiovascular diseases in India, it is our constant effort to bring newer technologies into the country, offering physicians the tools needed to provide the highest level of care and best possible outcomes for patients.
"Increased adoption of OCT imaging, when combined with advanced technology like AI, allows cardiologists to have a more precise and measurable way of supporting patients undergoing coronary stent procedures," said Tushar Sharma, general manager for Abbott’s vascular business in India and South Asia.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!